Alvotech
ALVO | NASDAQ
$4.41
+$0.22 (+5.25%)
At close: Nov 16, 2026, 4:00 PM ET
$4.41
$0.00 (-0.11%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Alvotech Company Profile
Company profile explainedCompany Profile
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
Key Executives
| Name | Position |
|---|---|
| Lisa Graver | Chief Executive Officer |
| Joseph E. McClellan | Chief Operating Officer |
| Linda Jonsdottir | Chief Financial Officer |
| Neha Patel | Chief Information Officer |
| Anthony Maffia | Chief Quality & Regulatory Officer |
| Balaji Venkataramanan Prasad | Chief Strategy Officer |
| Benedikt Stefansson | Vice President of Investor Relations and Global Communications |
| Kathryn Gunnarsson | Senior Vice President of Global Talent & People Experience |
| Sarah Macleod | Head of Global Communications |
| Vilhelm Robert Wessman | Founder & Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 20, 2026 | 6-K | Filing |
| Oct 14, 2026 | 6-K | Filing |
| Oct 07, 2026 | 6-K | Filing |
| Oct 05, 2026 | 6-K | Filing |
| Aug 31, 2026 | 6-K | Filing |
| Aug 21, 2026 | 6-K | Filing |
| Aug 19, 2026 | 6-K | Filing |
| Jul 29, 2026 | 6-K | Filing |
| Jul 01, 2026 | 6-K | Filing |
| Jun 30, 2026 | SC 13D/A | [Amend] Filing |
Alvotech
| Country | Luxembourg |
| IPO Date | Jun 16, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,279 |
| CEO | Lisa Graver |
Contact Details
9, Rue de Bitbourg Luxembourg,
LU 1273 Luxembourg
Stock Details
| Ticker Symbol | ALVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001898416 |
| CUSIP Number | L01800108 |
| ISIN Number | LU2458332611 |
| SIC Code | 2836 |
Recent News
- 4 days ago / marketbeat.comWhat Alvotech (ALVO) Said on Its Q3 Earnings Call
- 5 days ago / zacks.comAlvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates
- 5 days ago / globenewswire.comAlvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
- 13 days ago / zacks.comWill Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know
- 14 days ago / seekingalpha.comAlvotech: The Market Is Still Pricing The Broken Factory
- 15 days ago / globenewswire.comAlvotech to Present at Upcoming Investor Conferences in November
- 20 days ago / globenewswire.comAlvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
- 27 days ago / zacks.comNew Strong Sell Stocks for October 21st
- 28 days ago / globenewswire.comAlvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
- 1 month ago / globenewswire.comAlvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Add to Watchlist
Select watchlists to add or remove ALVO